Life Science Investing Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
Life Science Investing Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
Life Science Investing Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
Life Science Investing Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
CORRECTION: Nextech3D.ai Provides Shareholder Update on Krafty Labs Acquisition and Announces $321,917 CEO Investment
Goldgroup Secures Ownership of the San Francisco Gold Mine Acquiring 100% of Molimentales del Noroeste, S.A. De C.V.
